

Verquvo (vericiguat) Effective 07/01/2025 ☐ MassHealth UPPL Plan ☐ Prior Authorization ⊠Commercial/Exchange **Program Type** ☐ Quantity Limit □ Pharmacy Benefit **Benefit** ☐ Medical Benefit Specialty N/A Limitations **Medical and Specialty Medications** All Plans Phone: 877-519-1908 Fax: 855-540-3693 Contact Information **Non-Specialty Medications** Phone: 800-711-4555 All Plans Fax: 844-403-1029 **Exceptions** N/A

Overview

Prescriptions that meet the initial step therapy requirements will adjudicate automatically at the point of sale. If the prescription does not meet the initial step therapy requirements, the prescription will deny with a message indicating that prior authorization (PA) is required. Refer to the criteria below and submit a PA request for the members who do not meet the initial step therapy requirements at the point of sale.

Initial Step-Therapy Requirements:

First-Line: Medications listed on first-line are covered with prior-authorization.

Second-Line: Second-line medications will pay if the member has filled a first-line medications or a second-line medication within the past 180 days.

Coverage Guidelines

If a member does not meet the initial step therapy requirements, then approval of a second-line medication will be granted if the member has had a documented inadequate response, side effect, or allergy to a 1st-line medication.

FIRST-LINE FIRST-LINE	SECOND-LINE SECOND-LINE
Entresto (sacubitril/valsartan) - PA required	Verquvo (vericiguat)

Limitations

- 1. Approvals will be granted for 24 months.
- 2. The following quantity limits apply:

Drug Name and Dosage Form	Quantity Limit
Verquvo 2.5mg, 5mg, 10mg tablets	1 tablet per day

References

1. Verquvo (vericiguat) [prescribing information]. Rahway, NJ: Merck Sharp and Dohme Corp; July 2023.

Review History

11/17/2021: Created and Reviewed at Nov P&T; moved Verquvo to ST and require previous use of Entresto. Effective 1/1/22.

06/11/2025: Reviewed at June P&T. No changes. Effective 07/01/2025.

